Terms: = Liver cancer AND RAF1, Raf-1, 5894, P04049, ENSG00000132155, c-Raf, CRAF
162 results:
1. CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma.
Abou-Alfa GK; Geyer SM; Nixon AB; Innocenti F; Shi Q; Kumthekar P; Jacobson S; El Dika I; Yaqubie A; Lopez J; Huang B; Tang YW; Wen Y; Schwartz LH; El-Khoueiry AB; Knox JJ; Rajdev L; Bertagnolli MM; Meyerhardt JA; O'Reilly EM; Venook AP
Cancer Res Commun; 2024 Mar; 4(3):682-690. PubMed ID: 38363156
[TBL] [Abstract] [Full Text] [Related]
2. Comparative analysis of KRAS4a and KRAS4b splice variants reveals distinctive structural and functional properties.
Whitley MJ; Tran TH; Rigby M; Yi M; Dharmaiah S; Waybright TJ; Ramakrishnan N; Perkins S; Taylor T; Messing S; Esposito D; Nissley DV; McCormick F; Stephen AG; Turbyville T; Cornilescu G; Simanshu DK
Sci Adv; 2024 Feb; 10(7):eadj4137. PubMed ID: 38354232
[No Abstract] [Full Text] [Related]
3. Predictive Genetic Biomarkers for the Development of Peritoneal Metastases in Colorectal cancer.
Heuvelings DJI; Wintjens AGWE; Moonen L; Engelen SME; de Hingh IHJT; Valkenburg-van Iersel LB; den Dulk M; Beckervordersandforth J; Thijssen SGM; Leunissen DJG; Stassen LPS; Keszthelyi D; Mujagic Z; Speel EM; Bouvy ND
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629011
[TBL] [Abstract] [Full Text] [Related]
4. Transcriptional Regulation of Siglec-15 by ETS-1 and ETS-2 in Hepatocellular Carcinoma Cells.
Sheng K; Wu Y; Lin H; Fang M; Xue C; Lin X; Lin X
Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614238
[TBL] [Abstract] [Full Text] [Related]
5. Immune checkpoint therapy-elicited sialylation of IgG antibodies impairs antitumorigenic type I interferon responses in hepatocellular carcinoma.
Wu RQ; Lao XM; Chen DP; Qin H; Mu M; Cao WJ; Deng J; Wan CC; Zhan WY; Wang JC; Xu L; Chen MS; Gao Q; Zheng L; Wei Y; Kuang DM
Immunity; 2023 Jan; 56(1):180-192.e11. PubMed ID: 36563676
[TBL] [Abstract] [Full Text] [Related]
6. Custom gene expression panel for evaluation of potential molecular markers in hepatocellular carcinoma.
Pallerla SR; Hoan NX; Rachakonda S; Meyer CG; Van Tong H; Toan NL; Linh LTK; Giang DP; Kremsner PG; Bang MH; Song LH; Velavan TP
BMC Med Genomics; 2022 Nov; 15(1):235. PubMed ID: 36345011
[TBL] [Abstract] [Full Text] [Related]
7. Acteoside (Verbascoside): A Prospective Therapeutic Alternative against Hepatocellular Carcinoma by Inhibiting the Expression of AXL, FGFR, BRAF, TIE2 and raf1 Targets.
Kityania S; Nath R; Nath D; Patra JK; Talukdar AD
Comb Chem High Throughput Screen; 2023; 26(10):1907-1919. PubMed ID: 36321230
[TBL] [Abstract] [Full Text] [Related]
8. HDLBP Promotes Hepatocellular Carcinoma Proliferation and Sorafenib Resistance by Suppressing Trim71-dependent raf1 Degradation.
Yuan J; Lv T; Yang J; Wu Z; Yan L; Yang J; Shi Y; Jiang L
Cell Mol Gastroenterol Hepatol; 2023; 15(2):307-325. PubMed ID: 36244648
[TBL] [Abstract] [Full Text] [Related]
9. Arecoline promotes proliferation and migration of human HepG2 cells through activation of the PI3K/AKT/mTOR pathway.
Xie H; Jing R; Liao X; Chen H; Xie X; Dai H; Pan L
Hereditas; 2022 Jul; 159(1):29. PubMed ID: 35836300
[TBL] [Abstract] [Full Text] [Related]
10. Elevated serum CEA is associated with liver metastasis and distinctive circulating tumor DNA alterations in patients with castration-resistant prostate cancer.
Bray AW; Duan R; Malalur P; Drusbosky LM; Gourdin TS; Hill EG; Lilly MB
Prostate; 2022 Sep; 82(13):1264-1272. PubMed ID: 35766303
[TBL] [Abstract] [Full Text] [Related]
11. Oncolytic Vaccinia Virus Harboring
Jiang R; Qiu Y; Zhang X; Zhou N; Jia X; Chen K; Zhou Y; Ye T; Li G
Mar Drugs; 2022 Jun; 20(6):. PubMed ID: 35736181
[TBL] [Abstract] [Full Text] [Related]
12. Circ_CDR1as: A circular RNA with roles in the carcinogenesis.
Ghafouri-Fard S; Khoshbakht T; Hussen BM; Sarfaraz S; Taheri M; Ayatollahi SA
Pathol Res Pract; 2022 Aug; 236():153968. PubMed ID: 35667198
[TBL] [Abstract] [Full Text] [Related]
13. LXRα activation and Raf inhibition trigger lethal lipotoxicity in liver cancer.
Rudalska R; Harbig J; Snaebjornsson MT; Klotz S; Zwirner S; Taranets L; Heinzmann F; Kronenberger T; Forster M; Cui W; D'Artista L; Einig E; Hinterleitner M; Schmitz W; Dylawerska A; Kang TW; Poso A; Rosenfeldt MT; Malek NP; Bitzer M; Laufer S; Pichler BJ; Popov N; Schulze A; Zender L; Dauch D
Nat Cancer; 2021 Feb; 2(2):201-217. PubMed ID: 35122079
[TBL] [Abstract] [Full Text] [Related]
14. Elevated expression of RIT1 hyperactivates RAS/MAPK signal and sensitizes hepatocellular carcinoma to combined treatment with sorafenib and AKT inhibitor.
Sun L; Xi S; Zhou Z; Zhang F; Hu P; Cui Y; Wu S; Wang Y; Wu S; Wang Y; Du Y; Zheng J; Yang H; Chen M; Yan Q; Yu D; Shi C; Zhang Y; Xie D; Guan XY; Li Y
Oncogene; 2022 Jan; 41(5):732-744. PubMed ID: 34845378
[TBL] [Abstract] [Full Text] [Related]
15. Gd-EOB-DTPA-enhanced magnetic resonance imaging may help identify patients with hepatocellular carcinoma eligible for treatment targeted at raf1.
Mo Z; Ding H; Zhou X; Zeng Z; Long L
Abdom Radiol (NY); 2022 Jan; 47(1):209-220. PubMed ID: 34738148
[TBL] [Abstract] [Full Text] [Related]
16. Predictive biomarkers for systemic therapy of hepatocellular carcinoma.
Moldogazieva NT; Zavadskiy SP; Sologova SS; Mokhosoev IM; Terentiev AA
Expert Rev Mol Diagn; 2021 Nov; 21(11):1147-1164. PubMed ID: 34582293
[No Abstract] [Full Text] [Related]
17. CXCR4 promotes gefitinib resistance of Huh7 cells by activating the c-Met signaling pathway.
Zhao D; Yang Z; Chen C; Zhang Z; Yu Y; Li Z
FEBS Open Bio; 2021 Nov; 11(11):3115-3125. PubMed ID: 34555268
[TBL] [Abstract] [Full Text] [Related]
18. The molecular structure and role of LECT2 or CHM-II in arthritis, cancer, and other diseases.
Zhu S; Bennett S; Li Y; Liu M; Xu J
J Cell Physiol; 2022 Jan; 237(1):480-488. PubMed ID: 34550600
[TBL] [Abstract] [Full Text] [Related]
19. UHRF2 promotes Hepatocellular Carcinoma Progression by Upregulating ErbB3/Ras/Raf Signaling Pathway.
Sun J; Wu K; Chen S; Jiang S; Chen Y; Duan C
Int J Med Sci; 2021; 18(14):3097-3105. PubMed ID: 34400880
[TBL] [Abstract] [Full Text] [Related]
20. Exploiting lipotoxicity for the treatment of liver cancer.
Rudalska R; Zender L; Dauch D
Br J Cancer; 2021 Nov; 125(11):1459-1461. PubMed ID: 34302061
[TBL] [Abstract] [Full Text] [Related]
[Next]
